Reviewing Dyadic International (DYAI) & The Competition
Dyadic International (OTCMKTS: DYAI) is one of 32 public companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare Dyadic International to related businesses based on the strength of its dividends, risk, valuation, institutional ownership, earnings, profitability and analyst recommendations.
Volatility & Risk
Dyadic International has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, Dyadic International’s rivals have a beta of 4.22, meaning that their average stock price is 322% more volatile than the S&P 500.
This table compares Dyadic International and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Dyadic International||$760,000.00||-$2.14 million||-11.29|
|Dyadic International Competitors||$968.26 million||$63.67 million||12.50|
Dyadic International’s rivals have higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Dyadic International and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Dyadic International Competitors||-300.28%||-87.79%||-35.44%|
Insider and Institutional Ownership
0.0% of Dyadic International shares are held by institutional investors. Comparatively, 47.2% of shares of all “Commercial physical research” companies are held by institutional investors. 16.3% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This is a summary of recent ratings and price targets for Dyadic International and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Dyadic International Competitors||125||592||1368||55||2.63|
As a group, “Commercial physical research” companies have a potential upside of 19.12%. Given Dyadic International’s rivals higher possible upside, analysts plainly believe Dyadic International has less favorable growth aspects than its rivals.
Dyadic International rivals beat Dyadic International on 8 of the 10 factors compared.
About Dyadic International
Dyadic International, Inc., a biotechnology company, engages in the discovery, development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corporation to explore the potential of its C1 technology to produce two vital therapeutic proteins for human health indications; and the Sanofi-Aventis Deutschland GmbH to explore the potential of its C1 technology to produce various types of biologic vaccines and drugs of interest for human health indications. The company was founded in 1979 and is headquartered in Jupiter, Florida.
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.